Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2019 09:00 ET | Source: INmune Bio, Inc.

INmune Bio Inc. to Present at Advances in Immuno-Oncology USA Congress and at World Immunotherapy Congress in October

LA JOLLA, Calif., Oct. 08, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight...
September 24, 2019 10:20 ET | Source: INmune Bio, Inc.

CEO of INmune Bio Inc. Discusses Company Accomplishments at Nasdaq’s MarketSite and Announces Presentation at World Immunotherapy Congress

La Jolla, CA., Sept. 24, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight...
September 23, 2019 09:03 ET | Source: INmune Bio, Inc.

INmune Bio to Present XPro1595 for Treating Neuroinflammation in Alzheimer’s Disease at 2019 Alzheimer’s Association International Conference (AAIC) Satellite Symposium

LA JOLLA, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunotherapy company developing treatments which harness the patient’s innate immune system to fight...
September 17, 2019 09:05 ET | Source: INmune Bio, Inc.

INmune Bio Invited to Speak on Company’s Advancements in Cancer Treatments at the Targeting Innate Immunity Congress and MarketsandMarkets Next Gen Immuno-Oncology Congress

La Jolla, CA., Sept. 17, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight...
September 12, 2019 08:30 ET | Source: INmune BIO, Inc.

INmune Bio Inc. Announces USPTO Allowance of Key Patent Covering Its DN-TNFa Platform Technology for Treating Cancer

LA JOLLA, Calif., Sept. 12, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that reprogram the patient’s innate immune...
September 05, 2019 08:30 ET | Source: INmune BIO, Inc.

INmune Bio to Present at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, September 10th at 2:10 p.m. ET

LA JOLLA, Calif., Sept. 05, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight...
September 04, 2019 09:05 ET | Source: INmune BIO, Inc.

INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference

NeuLiv™ is the Third Drug Development Program From Company’s DN-TNF Platform Presentation is Scheduled for 2.10 p.m. on Sept. 9th LA JOLLA, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- INmune Bio,...
August 12, 2019 09:01 ET | Source: INmune BIO, Inc.

INmune Bio Reports Second Quarter 2019 Financial Results and Provides Shareholder Update

LA JOLLA, Calif., Aug. 12, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), an immunology company focused on developing treatments that harness the patient’s innate immune...
August 08, 2019 08:30 ET | Source: INmune BIO, Inc.

INmune Bio Appoints Biotechnology Executive Edgardo Baracchini as New Board Member

LA JOLLA, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight...
August 05, 2019 09:01 ET | Source: INmune BIO, Inc.

INmune Bio Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer

LA JOLLA, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight...